England’s cosmetic clinics face licensing uncertainty ahead
The Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act has already reshaped the cosmetic industry in Scotland, and England’s pending rules will soon follow. The new law, effective since May, criminalises unlicensed procedures, prohibits treatments for under-18s, and mandates that clinics operate from approved premises. While England’s framework mirrors Scotland’s structure, its delayed rollout leaves clinic owners uncertain about compliance timelines.
The Department of Health’s draft plan, released last August, categorises procedures into three risk tiers: green for low-risk treatments like microneedling, amber for botulinum toxin and dermal fillers requiring oversight by a regulated professional, and red for high-risk procedures such as non-surgical Brazilian butt lifts, which will only be permitted in CQC-registered clinics with healthcare professionals on staff. Without a confirmed launch date, however, businesses must prepare now to avoid costly disruptions.
Clinics face financial uncertainty without clear rules
Demand for cosmetic procedures remains strong, with a February report from the Women and Equalities Committee revealing that 52% of women aged 18 to 34 would consider undergoing a procedure in the future. Yet the absence of a clear timeline for England’s licensing rules forces owners to make critical purchasing decisions without full clarity. A £25,000 laser system, for example, financed over four years at 9% APR, costs roughly £620 per month. When servicing, insurance, and consumables are factored in, the fixed monthly cost rises to £770. At £75 per session, the device only breaks even after 12 treatments. If licensing changes mid-term, insurers may reject the equipment—or require additional training that was not part of the original purchase agreement.
Owners cannot delay addressing training requirements. A certificate of attendance alone proves no competency, and for laser and IPL systems, courses must align with a Core of Knowledge qualification to avoid licence denials. Suppliers differ widely in their approach: some include training in their packages, while others treat it as an optional extra. Without confirmation on which qualifications will be accepted under England’s rules, practitioners risk investing in non-compliant training that could invalidate their devices once licensing begins. The Women and Equalities Committee’s report emphasised this gap, calling on the government to define mandatory training standards before finalising the regulations.
Licensing delays complicate equipment and documentation
Documentation is another critical factor. Clinics must request UKCA or CE markings and clinical studies to support any performance claims, as insurers will demand these records. If a supplier takes two weeks to provide them, delays in licensing approval are likely. Repairs add further financial strain—a financed machine still incurs monthly payments while in the workshop. Loan-unit policies, where suppliers provide temporary replacements, can ease this burden, but not all suppliers offer them. The absence of such protections leaves clinics vulnerable to unexpected costs.
Consumables and handpiece replacements often erode profitability. A cheaper device with high per-treatment costs may become less economical over five years compared to a pricier model. Clinics should compare the total cost per session, including practitioner time and consumables, before finalising a purchase. For instance, a £75 session may deduct £10 for practitioner time and additional costs for consumables, leaving a net gain of £65 per treatment. At 12 sessions a month, the device breaks even, but at 40 sessions, it generates £1,830 in profit after fixed costs. If consumables or repairs increase expenses, a lower upfront cost could prove more expensive long-term.
